Long-term mexiletine for ventricular arrhythmia
Autor: | Joseph Stein, Philip J. Podrid, Bernard Lown, Geoffrey Hirsowitz, Steven Lampert |
---|---|
Rok vydání: | 1984 |
Předmět: |
Blood level
Male medicine.medical_specialty Ventricular Tachyarrhythmias Mexiletine Cardiac mortality Sudden death Refractory Internal medicine medicine Humans Dose-Response Relationship Drug Propylamines business.industry Incidence (epidemiology) Arrhythmias Cardiac Middle Aged medicine.disease Electrophysiology Heart failure Anesthesia Cardiology Drug Evaluation Female Cardiology and Cardiovascular Medicine business medicine.drug Follow-Up Studies |
Zdroj: | American heart journal. 107(5 Pt 2) |
ISSN: | 0002-8703 |
Popis: | Use of mexiletine was evaluated in 313 patients with ventricular tachyarrhythmias refractory to conventional antiarrhythmic drugs. Therapy with mexiletine was continued long term in 107 patients who responded to the drug and were free of side effects during a short-term evaluation in hospital. During an average follow-up of 22.8 months (0.1 to 70 months), 19 patients died (17.8%). Eleven patients had sudden death (3.6% per year), while six patients died of progressive congestive heart failure and two of noncardiac causes. Nonfatal ventricular arrhythmia recurred in 14 patients (4.9% per year). Overall, 25 patients had recurrent arrhythmia (incidence of 5.5% per year). Side effects occurred in 13 patients after an average of 5.1 months and were primarily gastrointestinal and neurologic. Sixty-one patients (57%) have continued on mexiletine therapy for an average of 32.2 months (1 to 70 months). Outcome during long-term therapy was not related to drug dose, blood level, or presenting arrhythmia. We conclude that if therapy with mexiletine is carefully evaluated and individualized, the drug is effective and well tolerated during long-term use. |
Databáze: | OpenAIRE |
Externí odkaz: |